"Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Sondel
P M
PM
Department of Pediatrics, University of Wisconsin Medical School, Madison 53792.
Hank
J A
JA
Kohler
P C
PC
Chen
B P
BP
Sosman
J
J
D000818:Animals; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000637:transplantation*; D008213:Lymphocyte Activation / Q000187:drug effects; D008218:Lymphocytosis / Q000139:chemically induced; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy
D007376:Interleukin-2